| abstract |
Disclosed herein are methods of treating fibrotic disorders by administering compounds selective for CAPN1, CAPN2, and/or CAPN9 such that side effects, off pathway interactions, and/or toxicities are minimized Such methods may, for example, minimize unintended effects of therapeutic compounds by providing dosing and dosage forms that minimize the level of unbound drug within the relevant tissues of a patient undergoing treatment. |